Alan Pollack, M.D., Ph.D. MR Simulation University Of ... · Prostate Anatomy MR-CT Fusion...
Transcript of Alan Pollack, M.D., Ph.D. MR Simulation University Of ... · Prostate Anatomy MR-CT Fusion...
Page
11
Alan Pollack, M.D., Ph.D.Alan Pollack, M.D., Ph.D.University Of MiamiUniversity Of Miami
Sylvester Comprehensive Cancer CenterSylvester Comprehensive Cancer Center
MR Simulation For MR Simulation For Prostate CancerProstate Cancer
MR SimulationMR Simulation
�� Prostate AnatomyProstate Anatomy
�� MRMR--CT FusionCT Fusion
�� Functional ImagingFunctional Imaging
�� Therapeutic ImplicationsTherapeutic Implications
22
33
The Benefit Of MRIThe Benefit Of MRI
�� Prostate ApexProstate Apex��ProstateProstate--rectal interfacerectal interface
�� Penile BulbPenile Bulb�� Tumor Location/ExtentTumor Location/Extent�� BladderBladder--Prostate InterfaceProstate Interface�� Seminal vesiclesSeminal vesicles�� Pelvic vesselsPelvic vessels�� Lymph nodesLymph nodes 44
Prostate AnatomyProstate AnatomyMcLaughlin et al, IJROBP 2005McLaughlin et al, IJROBP 2005
Page
55
Prostate AnatomyProstate AnatomyMcLaughlin et al, McLaughlin et al,
IJROBP 2005IJROBP 2005
66
Case 3 High Risk Case 3 High Risk CTCT--SagSagApex Not WellApex Not Well--VisualizedVisualized
77
Case 3 High Risk Case 3 High Risk MRIMRI--SagSagApex Better VisualizedApex Better Visualized
88
Case 3 High Risk CoronalCase 3 High Risk CoronalCTCT
Page
99
Case 3 High Risk CoronalCase 3 High Risk CoronalMRIMRI
1010
CT Overestimates Prostate CT Overestimates Prostate VolumeVolume
�� Roach et al, IJROBP 1996:Roach et al, IJROBP 1996:��““The mean prostate volume was 32% largerThe mean prostate volume was 32% larger…”…”
by CTby CT
�� RaschRasch et al, IJROBP 1999: et al, IJROBP 1999: ��The The ““average ratio between the CT and MR average ratio between the CT and MR
volumes was 1.4volumes was 1.4””��““CTCT--derived prostate volumes are larger than MR derived prostate volumes are larger than MR
derived volumes, especially toward the seminal derived volumes, especially toward the seminal vesicles and the apex of the prostate.vesicles and the apex of the prostate.””
1111
Retrograde Retrograde UrethrogramUrethrogram vsvs MRI MRI For Defining The Prostate ApexFor Defining The Prostate Apex
Rasch et al, IJROBP 1999
� Milosevic et al 1998 Radioth Oncol: ∼∼∼∼ 80% agreement between CT urethrogram and MR. 1212
MRI MRI vsvs CT: GTV DelineationCT: GTV Delineation
MR CT
Page
1313
Case 3 High Risk: Slice 89Case 3 High Risk: Slice 89
Tumor
1414
Penile Bulb/Penile Bulb/CavernosalCavernosal BodiesBodies
1515
MRI vs. CT: Hip ReplacementMRI vs. CT: Hip Replacement MR SimulationMR Simulation
�� Prostate AnatomyProstate Anatomy
�� MRMR--CT FusionCT Fusion
�� Functional ImagingFunctional Imaging
�� Therapeutic ImplicationsTherapeutic Implications
1616
Page
MR SimulationMR Simulation
�� No fiducials or Gold fiducials :No fiducials or Gold fiducials :�� CT Sim FirstCT Sim First
�� Calypso BeaconsCalypso Beacons�� MR Sim firstMR Sim first
�� Fusion based on bone and Fusion based on bone and soft tissue. soft tissue.
• Retrograde urethrograms are not performed.
1.5 T, 60 cm bore
Courtesy of Bob Price
Contoured on CT
Contoured on MR
MR-CT fusion based on boney anatomy
MR-based prostate-rectum interface
Mismatch arises from time of scan differences
Courtesy of Bob Price
CT-based prostate-rectum interface
Overlap (not including PTV)
Courtesy of Bob Price
CTMRI
Note that the prostate is in a different position relative to the femoral heads
MR And CT With Gold FiducialsMR And CT With Gold Fiducials
Courtesy of Bob Price
Page
CTMRI
Note that the prostate is in a different position relative to the femoral heads
CT With Calypso BeaconsCT With Calypso Beacons
Courtesy of Bob Price2222
MRMR--CT FusionCT Fusion
�� DonDon’’t outline from MR for soft tissue if there t outline from MR for soft tissue if there is discrepancy in the soft tissueis discrepancy in the soft tissue��Fusion should be based on both soft tissue and Fusion should be based on both soft tissue and
bony anatomybony anatomy
�� Gold markers on MR and CT can aid in soft Gold markers on MR and CT can aid in soft tissue fusiontissue fusion
�� Calypso beacons are on CT only and MR Calypso beacons are on CT only and MR should only be used as a reference (all should only be used as a reference (all outlining from CT)outlining from CT)
2323
MR SimulationMR Simulation
�� Prostate AnatomyProstate Anatomy
�� MRMR--CT FusionCT Fusion
�� Functional ImagingFunctional Imaging
�� Therapeutic ImplicationsTherapeutic Implications
2424
Page
2525
How Can BulkyHow Can Bulky--HypoxicHypoxic--MicrovesselMicrovessel Dense Dense Areas Be Identified And Better Targeted?Areas Be Identified And Better Targeted?
�� MRMR��MRS, Bold, DCE, DWMRS, Bold, DCE, DW
�� PETPET��11C11C--Choline, 11CCholine, 11C--AcetateAcetate
�� SpectSpect��PSMAPSMA
Testa et al, Radiology 2007
2626
Imaging To Identify Bulky Imaging To Identify Bulky Tumor RegionsTumor Regions
�� PretreatmentPretreatment��Target with EBRT boost, Target with EBRT boost, EBRT+BrachyEBRT+Brachy boost, boost,
EBRT+CryosurgeryEBRT+Cryosurgery boost, EBRT+FUS boostboost, EBRT+FUS boost�� MRMR--Guided FUSGuided FUS
��Reduce incidence of Reduce incidence of BxBx+ at 2+ at 2--3 yr3 yr
�� PostPost--treatmenttreatment��Biopsy at 2Biopsy at 2--3 years3 years
�� Decision to Decision to BxBx based on imaging?based on imaging?�� Target residual tumor before PSA riseTarget residual tumor before PSA rise
�� Treatment of residual tumor cells onlyTreatment of residual tumor cells only
2727
Is Failure Related To High Is Failure Related To High Volume Areas?Volume Areas?
�� TZTZ-- Left: 0/0Left: 0/0�� TZTZ--Right: 0/0Right: 0/0
3+41/15%
4+31/130%
4+31/170%
4+31/120%
0/1
0/13+41/1<5%
0/1
0/14+31/150%
Left
Base
Mid
Apex
Right
0/13+41/150%
Target with imaging
2828
PostPost--Treatment Biopsy ResultsTreatment Biopsy Results
�� TZTZ-- Left: 0/0Left: 0/0�� TZTZ--Right: 0/0Right: 0/0
0/1
0/14+31/115%
0/1
0/1
0/10/1
0/1
0/10/1
Left
Base
Mid
Apex
Right
0/13+41/15%
Target with imaging
Page
2929
�� 9 Patients9 Patients�� PrePre--RT and PostRT and Post--RT MRIRT MRI�� Salvage ProstatectomySalvage Prostatectomy
3030
PucarPucar et al, IJROBP 2007et al, IJROBP 2007
3131 3232
Page
3333
I
S
BoostTarget
ProstateProstate
BoostTarget
76 Gy, 68, 61, 53, 46, 38 76 Gy, 68, 61, 53, 46, 38
Price & Pollack
3434
Boost
10 Gy, 9, 8, 7, 6, 5
30 Gy, 27, 24, 21, 18, 15
10 Gy, 9, 8, 7, 6, 5
30 Gy, 27, 24, 21, 18, 15
EQD2 = EQD2 = D[(dD[(d + (+ (αα//ββ ))/(2 + ())/(2 + (αα//ββ ))] = 30 ))] = 30 GyGy {{αα//ββprostateprostate = 2.0 = 2.0 GyGy}}
Price & Pollack
3535
Pickett et al, MRSI In FollowPickett et al, MRSI In Follow--up up After EBRTAfter EBRT
Pretreatment
Post-treatment
3636
Page
3737
Lymphotropic SuperparamagneticNanoparticle lymph node imaging
agents (Combidex)3838
Benign : Post-contrastPre-contrast
Pre-contrast Malignant : Post-contrast
3939
MR Imaging For Prostate CancerMR Imaging For Prostate Cancer
�� There are gains in the use of MR There are gains in the use of MR imaging in RT planning and delivery, imaging in RT planning and delivery, and in followand in follow--up.up.
�� Need to test and incorporate better Need to test and incorporate better imaging methods for identifying imaging methods for identifying bulkybulky--hypoxichypoxic--microvesselmicrovessel dense dense diseasedisease